Evidence map›Paper›PMID 33593078›Full record

ArticleCell transplantation

Safety of Intraovarian Injection of Human Mesenchymal Stem Cells in a Premature Ovarian Insufficiency Mouse Model.

Hang-Soo Park, Rishi Man Chugh, Amro Elsharoud, Mara Ulin, Sahar Esfandyari, Alshimaa Aboalsoud, Lale Bakir, Ayman Al-Hendy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Application of adult stem cells in obstetrics and gynecology: A scoping review.European journal of obstetrics & gynecology and reproductive biology: X · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Hang-Soo ParkDepartment of Obstetrics and Gynecology, University of Chicago, IL, USA.ORCID 0000-0002-9130-8478
Rishi Man ChughDepartment of Surgery, College of Medicine, University of Illinois at Chicago, IL, USA.
Amro ElsharoudDepartment of Surgery, College of Medicine, University of Illinois at Chicago, IL, USA.
Mara UlinDepartment of Surgery, College of Medicine, University of Illinois at Chicago, IL, USA.
Sahar EsfandyariDepartment of Surgery, College of Medicine, University of Illinois at Chicago, IL, USA.
Alshimaa AboalsoudDepartment of Surgery, College of Medicine, University of Illinois at Chicago, IL, USA.
Lale BakirDepartment of Surgery, College of Medicine, University of Illinois at Chicago, IL, USA.
Ayman Al-HendyDepartment of Obstetrics and Gynecology, University of Chicago, IL, USA.
University of Illinois Chicago · USUniversity of Chicago · USTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary ovarian insufficiency (POI), a condition in which there is a loss of ovarian function before the age of 40 years, leads to amenorrhea and infertility. In our previously published studies, we demonstrated recovery of POI, correction of serum sex hormone levels, increase in the granulosa cell population, and restoration of fertility in a chemotherapy-induced POI mouse model after intraovarian transplantation of human bone marrow-derived mesenchymal stem cells (hBM-MSCs). While hBM-MSC may be a promising cell source for treatment of POI, there are few reports on the safety of stem cell-based therapy for POI. For future clinical applications, the safety of allogenic hBM-MSCs for the treatment of POI through intraovarian engraftment needs to be addressed and verified in appropriate preclinical models. In this study, we induced POI in C57/BL6 mice using chemotherapy, then treated the mice with hBM-MSCs (500,000 cells/ovary) by intraovarian injection. After hBM-MSC treatment, we analyzed the migration of engrafted cells by genomic DNA polymerase chain reaction (PCR) using a human-specific ALU repeat and by whole-body sectioning on a cryo-imaging system. We examined the possibility of transfer of human DNA from the hBM-MSCs to the resulting offspring, and compared the growth rate of offspring to that of normal mice and hBM-MSC-treated mice. We found that engrafted hBM-MSCs were detected only in mouse ovaries and did not migrate into any other major organs including the heart, lungs, and liver. Further, we found that no human DNA was transferred into the fetus. Interestingly, the engrafted cells gradually decreased in number and had mostly disappeared after 4 weeks. Our study demonstrates that intraovarian transplantation of hBM-MSCs could be a safe stem cell-based therapy to restore fertility in POI patients.

Indexed as

AdultAnimalsDisease Models, AnimalFemaleHumansInjections, Intra-ArterialMesenchymal Stem Cell TransplantationMicePrimary Ovarian Insufficiencymesenchymal stem cellprimary ovarian insufficiencytoxicology

Identifiers

PMID33593078
PMCPMC7894598
OpenAlexW3130909080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.